4 transcripts
GILD
Earnings call transcript
NASDAQ
2024 Q2
8 Aug 24
that highlight the strength of Gilead's innovation in HIV for both prevention and treatment. Our pipeline has the promise to extend our HIV leadership well
GILD
Earnings call transcript
NASDAQ
2024 Q1
25 Apr 24
market leadership in cell therapy, such as expand into community networks in the U.S., more than double our manufacturing capacity and move into new
GILD
Earnings call transcript
NASDAQ
2023 Q4
6 Feb 24
that could bring us closer to our goal of helping to end the HIV epidemic, building on Gilead's decades of leadership in HIV.
In COVID-19, today, we
GILD
Earnings call transcript
NASDAQ
2023 Q2
3 Aug 23
been with Gilead for 2 months and brings a wealth of oncology and leadership experience from Roche, Foundation Medicine and the Sarah Cannon Research
- Prev
- 1
- Next